Pontifax (Israel) IV, L.P. is Director & 10% Owner at Keros Therapeutics, Inc. (KROS). They have made 1 open-market trade across 1 company since 2020, most recently 2020-11-17.
CIK 0001726039
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $3.0M since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KROS | 1,122,768 | $12.0M |
Shares reported on the most recent Form 4, priced at the 2020-11-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KROS | BUY | 2020-11-17 | 2020-11-19 | $50.00 | $3.0M | +3.5% | +5.4% | -12.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.